Thomas Albini, MD, discusses the outcomes of the MUST trial—a 2-year, prospective study that evaluates visual acuity outcomes in patients implanted with RETISERT®. Dr. Albini comments on the outcomes and safety findings of RETISERT® when compared with standard systemic therapy in patients with chronic noninfectious uveitis.
RETISERT® (ﬂuocinolone acetonide intravitreal implant) 0.59 mg is a corticosteroid indicated for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye.
Click here for full prescribing information on RETISERT®
RETISERT and RETISERT READY are trademarks of Bausch & Lomb Incorporated or its affiliates.
© 2020 Bausch & Lomb Incorporated or its affiliates.